Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Weekly Snapshot

PharmaShots Weekly Snapshots (June 14 – 18, 2021)

Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to Supply and Use of Clinical-Grade Hystem Published: June 18, 2021 | Tags: Lineage, Option Agreement, Amasa Therapeutics, Clinical-Grade Hystem BioNTech Reports First Patient Dosing in P-II Clinical Trial of BNT111 to Treat Advanced Melanoma Published: June 18, 2021 | Tags: BioNTech, P-II, Clinical Trial, BNT111, […]Read More

Biotech

Lineage Signs an Exclusive Option Agreement with Amasa Therapeutics to

Shots: Lineage to receive an upfront payment in cash and, if the option is exercised, Lineage will be eligible for additional payments, including event-specific payments, royalties on net sales and sublicense fees and royalties Amasa gets an exclusive option to royalty-bearing license to use Lineage’s HyStem technology to develop and commercialize therapies for solid tumors […]Read More

DigiHealth Pharma

CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI

Shots: CytoReason reports the initiation of a project with Sanofi by utilizing its cell-centered models and deconvolution techniques to counsel mechanistic insights for each asthma endotype The focus of the project is to drive a better understanding of heterogeneity in asthma patients and identify stable and reproducible asthma endotypes alongwith associated diagnostic features by using […]Read More

Clinical Trials

BeiGene Reports First Patient Dosing in P-III AdvanTIG-302 Trial of

Shots: The first patient has been dosed in global P-III AdvanTIG-302 trial evaluating ociperlimab + tislelizumab in 605 naïve patients with locally advanced, unresectable, or metastatic NSCLC whose tumors exhibit high PD-L1 expression and do not harbor EGFR-sensitizing mutations or ALK translocations across the US, Australia & other countries globally The 1EPs of the trial […]Read More

Biotech

Kite Enter into a Partnership with Shoreline Biosciences to Develop

Shots: Shoreline is eligible to receive ~$2.3B including upfront, development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in Shoreline’s recent Series A financing The collaboration will utilize Shoreline’s iPSC differentiation and genetic reprogramming with Kite’s cell therapy to develop novel allogeneic therapies for hematologic malignancies Initially, the collaboration […]Read More

Insights+

Insights+: The US FDA New Drug Approvals in May 2021

The US FDA has approved 4 NDAs and 1 BLAs in  2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 29 novel products in 2021. Additionally, last year in 2020, the US FDA […]Read More